| Size | Price | Stock | Qty |
|---|---|---|---|
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Tazobactam (formerly CL298741; YTR830H; Zerbaxa) is a β-lactamase inhibitor approved for us in combination other antibiotics such as Ceftolozane (Zerbaxa) for the treatment of bacterial infections. Tazobactam is also combined with the extended spectrum β-lactam antibiotic piperacillin in the drug piperacillin/tazobactam, one of the preferred antibiotic treatments for nosocomial pneumonia caused by Pseudomonas aeruginosa.
| Targets |
β-lactam
|
|---|---|
| ln Vitro |
Tazobactam (CL-298741) (5 μg/mL; 18 hours) inhibits the growth of bacteria in a dose-dependent manner and possesses bactericidal activity[2].
With ID50 values of less than 10 μg/mL, respectively, tazobactam (CL-298741) (1–10 μg/mL; 6 hours; Prot. vulgaris and M. morgan) inhibits different types of β-lactamase activity[2]. |
| ln Vivo |
Tazobactam (CL-298741), administered intraperitoneally (i.p.) four times a day for 36 and 84 hours to BALB/c mice, reduces the quantity of bacteria in the mice and persists at low concentrations[1].
|
| Animal Protocol |
Animal Model: BALB/c mice[1]
Dosage: 1000 mg/kg Administration: Intraperitoneal injection; four times a day, for 36 and 84 hours Result: Reduced bacterial and neutrophil counts in BALF compared to the control group. |
| References |
| Molecular Formula |
C10H12N4O5S
|
|---|---|
| Molecular Weight |
300.29
|
| Exact Mass |
300.05
|
| Elemental Analysis |
C, 40.00; H, 4.03; N, 18.66; O, 26.64; S, 10.68
|
| CAS # |
89786-04-9
|
| Related CAS # |
Tazobactam sodium;89785-84-2
|
| Appearance |
White to off-white solid powder.
|
| SMILES |
O=C([C@@H]([C@@](CN1N=NC=C1)(C)S([C@]2([H])C3)(=O)=O)N2C3=O)O
|
| InChi Key |
LPQZKKCYTLCDGQ-WEDXCCLWSA-NLPQZKKCYTLCDGQ-WEDXCCLWSA-N
|
| InChi Code |
InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1
|
| Chemical Name |
(2S,3S,5R)-3-((1H-1,2,3-triazol-1-yl)methyl)-3-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
|
| Synonyms |
YTR830;YTR 830;YTR-830;AC7620;AC 7620;AC-7620;DB01606;DB 01606;DB-01606;CL298741;CL 298741;CL-298741;Tazobactam
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50~60 mg/mL ( 166.51~199.8 mM )
H2O : ~1 mg/mL ( 3.33 mM ) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.93 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.93 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.08 mg/mL (6.93 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3301 mL | 16.6506 mL | 33.3011 mL | |
| 5 mM | 0.6660 mL | 3.3301 mL | 6.6602 mL | |
| 10 mM | 0.3330 mL | 1.6651 mL | 3.3301 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA